[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368346-105":59,"doc-detail-368346-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","sitc-strategic-vision-prevention-premalignant-immunity-host-and-environmental-factors","SITC strategic vision - prevention, premalignant immunity, host and environmental factors","","Cancer immunotherapy improves outcomes for some patients by recruiting immune mechanisms to recognize and destroy malignant cells, while immunity also eliminates developing premalignant and malignant tumors. Progress in defining premalignant immunity and immune changes in progressing versus regressing lesions can enable immune prevention and immune interception. Key determinants include the premalignant immune environment and chronic inflammation, plus host genomics and environmental exposures that shape immunotherapy response. Antibiotics, obesity, and other modifiable lifestyle factors can disrupt gut microbiomes, sustain inflammation, and alter preventive and antitumor immunity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sitc-strategic-vision-prevention-premalignant-immunity-host-and-environmental-factors/368346/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sitc-strategic-vision-prevention-premalignant-immunity-host-and-environmental-factors/368346.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the core goal of SITC’s strategic vision in this article?","Question",{"text":113,"@type":114},"It focuses on prevention and premalignant immunity through immunoprevention and immune interception, and on how host factors influence response to immunotherapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why are premalignant lesions and chronic inflammation central to the proposed approach?",{"text":118,"@type":114},"Premalignant lesions reflect immune escape, and chronic inflammation drives premalignancy progression; understanding immune changes in lesions that progress versus regress helps design effective strategies.",{"name":120,"@type":111,"acceptedAnswer":121},"How can host and environmental factors affect immunotherapy outcomes?",{"text":122,"@type":114},"Host genomics and exposures such as antibiotics, obesity, smoking, diet, stress, and comorbidities can disrupt gut microbiomes, promote chronic inflammation, and suppress the immune responses needed for successful immunotherapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368346,1790334008,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Open access Position article and guidelines  \nSITC strategic vision: prevention, premalignant immunity, host and environmental factors  \nSasha E Stanton  ,1 Kristin G Anderson,2 Tullia C Bruno,3  \nChristian M Capitini  ,4 Mary L Disis,5 Jennifer McQuade,6 Laszlo Radvanyi,7 Claire Vanpouille-Box  ,8,9 Jennifer Wargo,10 Kelly J Baines,11 Megan M Y Hong,11 Adnan Rajeh,12 Raymond H Kim,7,13 Phillip Awadalla,7 Lauren K Hughes,7  \nSaman Maleki Vareki11,12,14  \nTo cite: Stanton SE, Anderson KG, Bruno TC, et al. SITC strategic vision: prevention, premalignant immunity, host and environmental factors. Journal for ImmunoTherapy of Cancer 2025;13:e010419 . doi:10 . 1136/ jitc-2024-010419  \nAccepted 17 March 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Sasha E Stanton;  \n[Sasha.Stanton@providence.org](Sasha.Stanton@providence.org)  \nABSTRACT  \nCancer immunotherapy has improved the survival of a subset of patients by harnessing the power of the immune system to find and destroy malignant cells. The immune system also protects the host by destroying developing premalignant and malignant tumors. Advancing our knowledge of premalignant immunity and immune changes seen in lesions that develop into invasive cancer versus those that regress offers an exciting opportunity to leverage the immune system for immune prevention and immune interception of premalignancy. Understanding the immune environment of premalignant lesions and how chronic inflammation plays a central role in the evolution of premalignancy is essential for developing effective immunoprevention and immune interceptions. Factors such as host genomics and environmental factors that affect premalignant immunity and the outcome of advanced cancers are equally important in determining the response to immunotherapy. The broad use of antibiotics and factors such as obesity can disrupt a healthy gut microbiome and drive chronic inflammation that suppresses preventive immunity or the antitumor immune response required for successful immunotherapy in advanced cancers. Modifiable lifestyle factors such as diet, obesity, smoking, and stress should be considered in designing immune prevention and interception studies, as well as for patients who receive immunotherapy for advanced cancer treatment. Other factors, such as the overall immune health of patients and existing comorbidities, affect both premalignant immunity and response to immunotherapy and, therefore, should be considered in managing patients with or without cancer. The Society for Immunotherapy of Cancer previously developed an overarching manuscript regarding the challenges and opportunities that exist in cancer immunotherapy, and this manuscript serves as an in-depth follow-up regarding the topics of premalignant immunity, immune interception, and immunoprevention, and the impact of the host on responding to immunotherapy.  \nINTRODUCTION  \nThe Society for Immunotherapy of Cancer gathered a diverse group of experts across the cancer immunotherapy landscape to  \nidentify challenges and opportunities in cancer immunotherapy, which were outlined in the prefatory manuscript.1 This manuscript serves to further define and address two of the outlined topics: (1) premalignant immunity, immune interception and immunoprevention and (2) the impact of the host on response to immune therapy and presents the current challenges and opportunities that exist. The immune system plays a vital role in screening and eradicating potentially neoplastic cells in the body and the evolution of premalignant and malignant tumors. Immunotherapy leverages the tumoricidal potential of immune cells, primarily T cells, in advanced and metastatic cancers. Furthermore, clinical trials of immune checkpoint inhibitors (ICIs) in the neoadjuvant setting in lung cancer, triple-negative bre","cbCaigYjncjIrzqf","https://ap.wps.com/l/cbCaigYjncjIrzqf","pdf",1490893,"English","# Abstract\n## Introduction\n## Prevention and Premalignant Immunity","[{\"question\":\"What is the core goal of SITC’s strategic vision in this article?\",\"answer\":\"It focuses on prevention and premalignant immunity through immunoprevention and immune interception, and on how host factors influence response to immunotherapy.\"},{\"question\":\"Why are premalignant lesions and chronic inflammation central to the proposed approach?\",\"answer\":\"Premalignant lesions reflect immune escape, and chronic inflammation drives premalignancy progression; understanding immune changes in lesions that progress versus regress helps design effective strategies.\"},{\"question\":\"How can host and environmental factors affect immunotherapy outcomes?\",\"answer\":\"Host genomics and exposures such as antibiotics, obesity, smoking, diet, stress, and comorbidities can disrupt gut microbiomes, promote chronic inflammation, and suppress the immune responses needed for successful immunotherapy.\"}]","SITC strategic vision - prevention, premalignant immunity, host and environmental factors | PDF",1790176416,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0ddc8efe9162f2e8d828224122a62f3.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8512ec8eedf47d8ca6002888f01f191.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cbb90f19f330ec05992359b1f9c443b.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b55a3f2daff89ab49a40f275894d50c.webp",980,1306]